Human immunodeficiency virus type 1 Gag-Pol-Nef polyprotein (HIV-1 Gag/RT/Nef)

The Human immunodeficiency virus type 1 (HIV-1) Gag-Pol-Nef polyprotein target is a multi-antigen complex comprising the matrix (p17), capsid (p24), reverse transcriptase (RT), and negative regulatory factor (Nef) proteins. These components are essential for the viral life cycle: p17 and p24 provide structural integrity and facilitate viral assembly, RT catalyzes the conversion of viral RNA into DNA, and Nef modulates the host immune environment to favor viral persistence (UniProt P03366, P04591, P03406). This specific combination of antigens is primarily utilized in the development of T-cell-based vaccines, such as the MRKAd5 (V520) candidate, designed to elicit robust CD8+ cytotoxic T-lymphocyte responses against conserved viral epitopes (Buchbinder et al., 2008). While the RT component is a well-established target for small-molecule antiretroviral drugs like zidovudine and efavirenz, the entire Gag-Pol-Nef complex serves as a focal point for immunotherapeutic strategies aimed at controlling viral replication and reducing the reservoir of infected cells (Autran et al., 2004). Clinical trials targeting this complex have highlighted significant challenges, including the impact of pre-existing vector immunity and the risk of enhanced viral acquisition in certain cohorts (McElrath et al., 2008). Consequently, this target remains central to HIV research, representing a critical interface between viral structural biology, enzymatic replication, and immune evasion.

Other names

Gag-Pol-NefHIV-1 multi-antigen vaccine targetp17/p24/RT/Nef fusionMRKAd5 antigensHIV-1 Gag-RT-Nef

Active immunization to induce T-cell mediated lysis of infected cells and competitive or non-competitive inhibition of viral DNA synthesis.